Roche Products Australia Pty Ltd

Regulatory activities for this sponsor.

3 result(s) found, displaying 1 to 3

AusPAR: Tecentriq

14 March 2023

Australian Public Assessment Report (AusPAR)

AusPAR for Tecentriq (atezolizumab) for conversion of provisionally registered indication (for treatment of locally advanced or metastatic triple negative breast cancer (mTNBC)) to full registration (withdrawn).
AusPAR: Tecentriq

8 August 2022

Australian Public Assessment Report (AusPAR)

New AusPAR for Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.
AusPAR: Bevacizumab

3 November 2014

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Bevacizumab